CDXS - codexis.com Operating income before deduction of amortization
Codexis, Inc. (CDXS) EBITDA dynamics are supported by biocatalyst sales and ECO Synthesis licenses. Growth is driven by the creation of clean catalysts for the industry and synergy with pharma behemoths via CodeEvolver. The 0.00 metric indicates the current level of operational efficiency, confirming the business's strength, although the upward trend may signal a risk of overvalued shares.
Summary analytical data breakdowns for Codexis (CDXS)
- share price and expert price forecast:
- market capitalization statistics:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Codexis, Inc.|CDXS - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Codexis Inc|CDXS - Company Aggregate Debts|Debt to Book Value Codexis, Inc.|CDXS - Company Long-Term Liabilities|Short-Term Debt Volume Codexis, Inc.|Quick Liquidity Indicator codexis.com
- company profitability and valuation multiples indicators:
CDXS - Net Profit|Net Profit Forecast Codexis, Inc.|CDXS - Price to Earnings Ratio|Price to Future Earnings Ratio Codexis Inc|CDXS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Codexis, Inc.|CDXS - Operating profit EBITDA|Earnings per share for the last 12 months Codexis, Inc.|CDXS - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months codexis.com|CDXS - Earnings growth in current year|Earnings growth forecast for next year Codexis, Inc.
Summary company analytics:CDXS - Codexis, Inc.
This metric reflects net cash flow from operating activities before depreciation, allowing for an assessment of the ability of Codexis, Inc. (CDXS) to convert unique patented enzymes into actual revenue. By analyzing operating profit trends, an investor can see how the company's pricing power in bioengineering offsets inflationary costs, transforming technological superiority into a sustainable financial base and operational flexibility.
Competitor analysis for Codexis, Inc.
TEM: Operating profit before amortization|Qiagen N.V. - Operating profit EBITDA|Operating income before deduction of amortization ionispharma.com IONS|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|RNA - Operating income before deduction of amortization|Operating profit before deduction of amortization CRSP|WGS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RARE|Operating income before deduction of amortization beamtx.com|Profit before payment of interest, taxes and amortization Sarepta SRPT|TWST: Operating profit before amortization|10x Genomics Corp - Operating profit EBITDA|Intellia Corp (NTLA) - Operating profit before deduction of amortization|STOK (Stoke Therapeutics) - Operating profit before deduction of amortization|BLFS - Operating income before deduction of amortization|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Operating profit EBITDA SION|Prime Medicine Bio - Operating profit before amortization|Taysha Gene Therapies - Operating profit before deduction of amortization|QURE: Operating profit before amortization|MGTX - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization REGENXBIO Inc RGNX|SLDB: Operating profit EBITDA|Operating profit before amortization OCGN|Profit before payment of interest, taxes and amortization Pacific Biosciences|Operating profit before amortization BNTC (benitec.com)|Operating profit EBITDA DSGN|Operating profit EBITDA Rocket Pharma (RCKT)|Operating profit EBITDA FDMT (4D Molecular Therapeutics Inc)|LXEO - Operating profit before deduction of amortization|KRRO - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization editasmedicine.com|SLN: Operating profit EBITDA|Operating profit before amortization PRQR|SGMO (Sangamo) - Operating profit EBITDA|Profit before interest, taxes and amortization Nautilus Biotechnology Inc NAUT|Operating profit before deduction of amortization MGX (Metagenomi, Inc.)|precisionbiosciences.com - Operating profit before amortization|Operating profit EBITDA GBIO (Generation Bio)|Operating income before deduction of amortization Boundless Bio Inc. (BOLD)|XCUR - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Imunon, Inc. IMNN|PHIO (phiopharma.com) - Operating profit before deduction of amortization|Mustang Bio - Income before deduction of interest, taxes and amortization|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Bionano (BNGO) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|bluebird bio, Inc - Operating profit before amortization|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|OMGA - Operating profit before deduction of amortization|OMIC: Operating profit before deduction of amortization|Operating income before deduction of amortization Regulus Therapeutics, Inc. RGLS|SYRS: Operating profit EBITDA|Operating profit before deduction of amortization Telesis Bio, Inc|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|Operating profit before amortization UBX (unitybiotechnology.com)
